全文获取类型
收费全文 | 238510篇 |
免费 | 38982篇 |
国内免费 | 8963篇 |
专业分类
耳鼻咽喉 | 5866篇 |
儿科学 | 6259篇 |
妇产科学 | 3453篇 |
基础医学 | 13821篇 |
口腔科学 | 3152篇 |
临床医学 | 38752篇 |
内科学 | 60054篇 |
皮肤病学 | 8232篇 |
神经病学 | 19388篇 |
特种医学 | 9546篇 |
外国民族医学 | 63篇 |
外科学 | 49167篇 |
综合类 | 15665篇 |
现状与发展 | 105篇 |
一般理论 | 3篇 |
预防医学 | 12297篇 |
眼科学 | 5871篇 |
药学 | 10249篇 |
82篇 | |
中国医学 | 4985篇 |
肿瘤学 | 19445篇 |
出版年
2024年 | 994篇 |
2023年 | 6308篇 |
2022年 | 5152篇 |
2021年 | 7855篇 |
2020年 | 9538篇 |
2019年 | 5209篇 |
2018年 | 10436篇 |
2017年 | 10209篇 |
2016年 | 10972篇 |
2015年 | 12553篇 |
2014年 | 20401篇 |
2013年 | 19750篇 |
2012年 | 11771篇 |
2011年 | 12637篇 |
2010年 | 14645篇 |
2009年 | 17466篇 |
2008年 | 9918篇 |
2007年 | 8467篇 |
2006年 | 10842篇 |
2005年 | 8263篇 |
2004年 | 5759篇 |
2003年 | 4488篇 |
2002年 | 4257篇 |
2001年 | 5706篇 |
2000年 | 5157篇 |
1999年 | 5717篇 |
1998年 | 5295篇 |
1997年 | 5043篇 |
1996年 | 4570篇 |
1995年 | 4267篇 |
1994年 | 2825篇 |
1993年 | 2165篇 |
1992年 | 2081篇 |
1991年 | 2013篇 |
1990年 | 1602篇 |
1989年 | 1645篇 |
1988年 | 1401篇 |
1987年 | 1195篇 |
1986年 | 1127篇 |
1985年 | 900篇 |
1984年 | 635篇 |
1983年 | 593篇 |
1982年 | 552篇 |
1981年 | 443篇 |
1980年 | 387篇 |
1979年 | 336篇 |
1978年 | 328篇 |
1977年 | 396篇 |
1975年 | 277篇 |
1972年 | 302篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
6.
7.
Eric S. Zhou Larissa Nekhlyudov Sharon L. Bober 《Translational andrology and urology》2015,4(2):218-231
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples. 相似文献
8.
9.
10.